Companies in #Onychomycosis
Found 1 company operating in this sector.
Turn Therapeutics is a clinical-stage biotechnology company developing targeted, localized, non-systemic therapies for inflammatory and infectious skin diseases. Its lead program, GX-03, is a topical IL-36/IL-31 pathway inhibitor in Phase 2 for moderate-to-severe atopic dermatitis; a July 2026 interim analysis supported expanding Stage 2 enrollment to roughly 120-135 patients, with topline data targeted for Q4 2026 and a Phase 2a study in hidradenitis suppurativa planned. The company's PermaFusion formulation platform is being developed with Medline under a global supply, development and license agreement, and supports a thermostable intranasal vaccine initiative. Turn Therapeutics (formerly Global Health Solutions, renamed in September 2025) completed a direct listing on Nasdaq in October 2025 and named former FDA Commissioner Stephen M. Hahn as Executive Clinical and Regulatory Lead in May 2026.